Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Bladder Cancer.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Solid Tumor.

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Thymoma (Thymic Epithelial Tumor).

40

40

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Kidney Cancer (Renal Cell Cancer).

40

40

Fierce Pharma

NOVEMBER 3, 2023

The agency previously gave the generic a tentative approval before some patents expire in 2029. . | The D.C. federal court denied Alvogen's bid to force the FDA to grant full approval to its proposed Xifaxan generic.

FDA 262

FDA Pharmaceutical 262

Fierce Pharma

AUGUST 30, 2023

After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.

187

187

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Marketing 83

Marketing Manufacturing Media Pharmaceutical 83

Pharmaceutical Commerce

JANUARY 5, 2024

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

Marketing 52

Marketing 52

Pharmaceutical Technology

SEPTEMBER 22, 2023

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

59

59

Pharmaceutical Technology

JULY 31, 2023

According to GlobalData, it is projected that the market for hepatitis B treatments will experience a sharp increase over the next six years.

Marketing 52

Marketing 52

Clarivate

JANUARY 8, 2024

Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. billion in 2029 revenues.

Marketing 59

Marketing Patients Healthcare Healthcare 59

Pharmaceutical Technology

OCTOBER 23, 2023

The Remicade biosimilar is forecasted to have sales of $2.3bn by 2029 as a subcutaneous form is approved for the US market.

FDA 52

FDA Sales Marketing 52

Pharmaceutical Technology

AUGUST 31, 2023

Daiichi Sankyo and AstraZeneca’s blockbuster anti-cancer drug Enhertu could become a pan-tumour drug, with projected sales of $9.9bn by 2029.

FDA 52

FDA Sales 52

Pharmaceutical Technology

NOVEMBER 1, 2023

The Amgen biosimilar Wezlana has been approved for all indications and is forecasted to yield $455m in 2029.

FDA 52

FDA 52

Pharmaceutical Technology

JULY 20, 2023

By 2029, RSV drugs are forecast to surpass $9bn in sales, This surge can be attributed to recent developments in preventative measures.

Marketing 40

Marketing Sales 40

Pharmaceutical Technology

APRIL 28, 2023

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Sales 52

Sales Marketing Medical Patients 52

European Pharmaceutical Review

FEBRUARY 21, 2024

Research predicts 2029 small molecule oncology market leaders The post EGFR inhibitor could provide major advance in lung cancer appeared first on European Pharmaceutical Review. Results from a Phase III trial in the neoadjuvant setting are expected later in 2024.

Distribution 90

Distribution Patients Medical Pharmaceutical 90

Pharmaceutical Technology

SEPTEMBER 23, 2022

It is expected to expire on 21 January 2029, with paediatric exclusivity lasting until 21 July 2029. It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Merck’s second patent covers the co-formulation of sitagliptin and metformin present in Janumet.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69

Pharmaceutical Technology

MAY 12, 2023

GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). GlobalData analysts predict the total revenue to be generated from currently marketed Seagen ADCs to be roughly $30bn through 2029. targeting ADC.

Sales 64

Sales Marketing 64

European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Once equipped, the facility is expected to create a total of 800 jobs: 700 jobs in the new API facility and 100 jobs in the new packaging facility.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 98

European Pharmaceutical Review

FEBRUARY 5, 2024

Research predicts 2029 small molecule oncology market leaders A “big step forward” for biotech innovation In a similar move, legislation to restore immediate R&D expensing was passed in the US House of Representatives on 31 January 2024.

Food and Drug Administration 80

Food and Drug Administration Medicine Food Pharmaceutical 80

Pharmaceutical Technology

APRIL 24, 2023

billion in 2029, while Calquence is expected to make $5.31 billion in 2029. According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98 billion in the same year. While Imbruvica sales were $3.78 GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

Pharmaceutical Technology

MAY 10, 2023

billion in global sales in 2029, while Truvada estimates amount to $30 million. Truvada has since gone generic, with Teva Pharmaceuticals launching the first FDA-approved Truvada generic in October 2020. According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Descovy is estimated to yield $1.83

Government 105

Government FDA Pharmaceutical Pharma 105

European Pharmaceutical Review

JUNE 12, 2023

The facility is expected to start producing API by early 2029. Novo Nordisk explained that, according to internal calculations, production in the future facility in Hillerød will reduce water consumption by more than 40 percent and energy consumption by more than one third, compared to similar API processes in other facilities.

Manufacturing 88

Manufacturing Government Pharmaceutical Medicine 88

European Pharmaceutical Review

JUNE 28, 2023

If commercialisation is successful, obicetrapib is expected to value $619 million in sales by 2029, stated GlobalData. According to GlobalData, the CETP inhibitor obicetrapib is in the pipeline for dyslipidaemia. The treatment is expected to launch in 2028 in the US, EU, and Japan. appeared first on European Pharmaceutical Review.

Patients 82

Patients Sales Medical Pharmaceutical 82

Pharmaceutical Technology

JUNE 13, 2023

Construction has already commenced, with API production expected to begin by early 2029. The new facility will be future-proof and cost-effective, with a focus on optimal and compact process flows to reduce water and energy consumption. The expansion project is anticipated to create 340 new jobs.

Manufacturing 52

Manufacturing Government Medicine Patients 52

European Pharmaceutical Review

JANUARY 2, 2024

According to the research, the global cell and gene therapy market is predicted to value $80 billion by 2029. The field of oncology is anticipated to hold 44 percent of the market by this year.

Manufacturing 83

Manufacturing Marketing Engineering Pharma 83

Pharmaceutical Technology

MAY 23, 2023

billion in 2029. In May 2021, Amgen’s Lumakras was approved for use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Lumakras, also known as sotorasib, has projected sales of $1.47

Pharma 52

Pharma Sales Pharmaceutical Patients 52

pharmaphorum

NOVEMBER 18, 2022

Its CW-2029 – developed in collaboration with AbbVie – is an investigational, conditionally activated ADC directed towards CD71 and has demonstrated encouraging anti-tumour activity in patients with squamous non-small cell lung cancer (NSCLC).

Biopharma 87

Biopharma Physicians Sales Patients 87

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. billion in 2029, although its sales growth is likely to continue beyond 2029. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9

Marketing 52

Marketing Physicians Competition Leads 52

Clarivate

MARCH 20, 2024

While assurances were made regarding the continuation of the REF in 2029, apprehensions lingered regarding timelines and escalating costs associated with the assessment. Towards a more inclusive research community The summit also addressed the imperative of fostering diversity and inclusivity within the research community.

Government 64

Government Recruitment Media Management 64

pharmaphorum

OCTOBER 26, 2022

Ofev is, however, heading for patent expiry in 2029, and Boehringer is looking to BI 1015550 to maintain the franchise beyond that date, and also to improve the treatment of IPF, which remains incurable. First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5

Recruitment 92

Recruitment Prospecting Marketing Patients 92

European Pharmaceutical Review

AUGUST 21, 2023

billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. Merck & Co Merck & Co reached third in ranking, due to 8.4 percent market capitalisation growth due to its $10.8 billion acquisition of Prometheus Biosciences.

Biopharma 86

Biopharma Marketing Sales Medicine 86

pharmaphorum

SEPTEMBER 30, 2022

8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029. That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No.

Marketing 57

Marketing Sales Competition FDA 57

Pharmaceutical Technology

APRIL 4, 2023

billion in 2029. Tagrisso was approved for use as a first-line treatment for metastatic NSCLC with EGFR mutation in April 2018. According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

Pharmaceutical Technology

MARCH 27, 2023

Veklury is currently a blockbuster drug, but its revenues are predicted to drop by 2029. Additional approvals of the drug across a greater range of geographies will increase its demand. There are ongoing Phase II/III trials of Veklury in children.

Manufacturing 52

Manufacturing FDA Marketing Pharmaceutical 52